FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).

March 21, 2025

Vol.51 No.11

Accelerating translational research in leukemia: The City of Hope approach

As a physician-scientist, I navigate the intersection of laboratory research and clinical care every day. At City of Hope, our mission is to rapidly translate groundbreaking discoveries into effective treatments for patients with hematologic malignancies, particularly acute leukemias. This is possible due to a unique combination of infrastructure and culture combined with an unwavering sense of urgency.

Florida leukemia rates rising rapidly as population ages, study shows

Driven by a steady influx of retirees, Florida now has the highest leukemia rates of any U.S. state and the disease is the fastest-rising cancer type statewide, according to research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

March 14, 2025

Vol.51 No.10

Drugs & Targets

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

FDA granted Orphan Drug designation to rhenium obisbemeda (186Re) for the treatment of leptomeningeal metastases in patients with lung cancer.

March 14, 2025

Vol.51 No.10

Clinical Roundup

CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study

B-cell acute lymphoblastic leukemia is a common type of ALL in adults.

March 07, 2025

Vol.51 No.09

Clinical Roundup

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

The phase III VERIFY trial, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide (PTG-300) or placebo, as an add-on to standard of care treatment, met its primary endpoint of proportion of patients achieving response.

March 07, 2025

Vol.51 No.09

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

YOU MAY BE INTERESTED IN

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

Accelerating translational research in leukemia: The City of Hope approach

Florida leukemia rates rising rapidly as population ages, study shows

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

Renew today!

Subscriber content

Never miss an issue!

Login

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

YOU MAY BE INTERESTED IN

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

Accelerating translational research in leukemia: The City of Hope approach

Florida leukemia rates rising rapidly as population ages, study shows

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

Never miss an issue!

Login

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)